Zobrazeno 1 - 10
of 491
pro vyhledávání: '"Janus kinase (JAK)"'
Autor:
Andrea Rubbert-Roth, Koji Kato, Boulos Haraoui, Maureen Rischmueller, Yanxi Liu, Nasser Khan, Heidi S. Camp, Ricardo M. Xavier
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1197-1215 (2024)
Abstract Introduction The safety and efficacy of upadacitinib 15 mg (UPA15) through week 216 was evaluated in patients with rheumatoid arthritis (RA) from the long-term extension (LTE) of the phase 3 SELECT-CHOICE study. Methods Patients with RA refr
Externí odkaz:
https://doaj.org/article/d313932347fc4677b9fb4fe93f411d0d
Autor:
Martyna Choinka, Małgorzata Komarów, Natalia Wdowiak, Karina Lissak, Zuzanna Szczepaniak, Agata Konopka, Jakub Kalisiak, Dominika Karasińska
Publikováno v:
Quality in Sport, Vol 22 (2024)
Atopic dermatitis is a long-term inflammatory skin disease caused by factors such as skin barrier dysfunction and immune system dysregulation . Currently, the first-line treatment for atopic dermatitis involves the use of topical glucocorticosteroids
Externí odkaz:
https://doaj.org/article/25fa99aead4d4e9f8bcc4c6210efa7a4
Autor:
Andrea Rubbert-Roth, Adriana M. Kakehasi, Tsutomu Takeuchi, Marc Schmalzing, Hannah Palac, Derek Coombs, Jianzhong Liu, Samuel I. Anyanwu, Ralph Lippe, Jeffrey R. Curtis
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 1, Pp 97-112 (2023)
Abstract Introduction This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated with upadacitinib (UPA
Externí odkaz:
https://doaj.org/article/a4e890c38a81458f8f0e15e86b14da3d
Publikováno v:
Advances in Rheumatology, Vol 63, Iss 1, Pp 1-9 (2023)
Abstract Objective To compare the efficacy and safety between baricitinib (BARI) and tofacitinib (TOFA) for the treatment of the rheumatoid arthritis (RA) patients receiving methotrexate (MTX) in clinical practice. Methods This retrospective study re
Externí odkaz:
https://doaj.org/article/ed4c8fcc5ff24a8bb6b453edfb8e2369
Autor:
Aleksandra Rzewińska, Jakub Szlęk, Damian Dąbrowski, Ewelina Juszczyk, Katarzyna Mróz, Heikki Räikkönen, Mia Siven, Maciej Wieczorek, Przemysław Dorożyński
Publikováno v:
Pharmaceutics, Vol 16, Iss 9, p 1157 (2024)
The pursuit of targeted therapies for cytokine-dependent diseases has led to the discovery of Janus kinase (JAK) inhibitors, a promising class of drugs. Among them, CPL409116, a selective dual JAK and rho-associated protein kinase inhibitor (ROCK), h
Externí odkaz:
https://doaj.org/article/6049c0b9f7b84a35a5814f9bec6fdeb6
Autor:
Chan-yuan Wu, Qian Wang, Jian Shi, Xiu-ying Zhang, Rong Du, Jie-ruo Gu, Qi-huan Liu, Jiao Yu, Jia-wei Xu, Yan-jie Zhang, Hao Zhu, Meng-tao Li, Xiao-feng Zeng
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1609-1622 (2023)
Abstract Introduction Baricitinib, a JAK1/JAK2 inhibitor, is approved for treatment of moderate-to-severe rheumatoid arthritis (RA) in China. This single-arm, prospective, multi-center, post-marketing safety study (PMSS) evaluated the safety and effe
Externí odkaz:
https://doaj.org/article/a08f62f4f5654f7aa592d298a858cd2d
Autor:
Leslie R. Harrold, Patrick Zueger, W. Benjamin Nowell, Taylor Blachley, Amy Schrader, Paul R. Lakin, David Curtis, Laura Stradford, Shilpa Venkatachalam, Namita Tundia, Pankaj A. Patel
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1519-1533 (2023)
Abstract Introduction The impact of upadacitinib on rheumatoid arthritis (RA) symptoms was evaluated during the first 12 weeks of treatment via patient-reported outcomes (PROs) using a mobile health application (app). Methods Participating rheumatolo
Externí odkaz:
https://doaj.org/article/dd8856bcc29541ef9868140fa069a7a6
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). For many years, corticosteroids have been the mainstay treatment for GVHD, but cases of steroid-refrac
Externí odkaz:
https://doaj.org/article/4f8d7130a7ac45a0850f44778138ca30
Publikováno v:
BMC Molecular and Cell Biology, Vol 24, Iss 1, Pp 1-19 (2023)
Abstract Janus kinase 3 (JAK3) is a member of the JAK family of tyrosine kinase proteins involved in cytokine receptor-mediated intracellular signal transduction through the JAK/STAT signaling pathway. JAK3 was previously shown as differentially expr
Externí odkaz:
https://doaj.org/article/18f086c09b364892a85366bffc8148d9
Autor:
Xenofon Baraliakos, Roberto Ranza, Andrew Östör, Francesco Ciccia, Laura C. Coates, Simona Rednic, Jessica A. Walsh, Kevin Douglas, Tianming Gao, Koji Kato, In-Ho Song, Fabiana Ganz, Atul Deodhar
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-13 (2023)
Abstract Background The objective of this post-hoc analysis was to assess the efficacy and safety of upadacitinib in psoriatic arthritis (PsA) patients with axial involvement. Methods Post-hoc analysis of SELECT-PsA 1 and SELECT-PsA 2 in patients ran
Externí odkaz:
https://doaj.org/article/90d18e6abacf401699f4e7aeeb68ccd1